http://www.pharmaweblog.comPharmaceutical and biotech science and businessenFri, 07 Nov 2008 12:13:13 -0600http://feeds.feedburner.com/PharmasCuttingEdgePosts?format=skinhttp://api.feedburner.com/awareness/1.0/GetFeedData?uri=PharmasCuttingEdgePostshttp://www.feedburner.comhttp://www.feedburner.com/fb/images/pub/fb_pwrd.gifThis is an XML content feed. It is intended to be viewed in a newsreader or syndicated to another site, subject to copyright and fair use.http://www.pharmaweblog.com/2008/11/07/cb1-antagonist-update-and-a-poor-excuse/I recently reported on Sanofi-Aventis' decision to pull rimonabant from EU shelves.  Since then, S-A has stoppedall rimonabant clinical development.  I also told you that clinical success of Pfizer's Phase 3 CB1 antagonist, CP-945,598, seemed dubious.  Yesterday, Pfizer pulled the plug on their drug, citing "changing regulatory perspectives on the risk/benefit ...<div class="feedflare"> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?a=iwkHN"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?i=iwkHN" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?a=O9mwN"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?i=O9mwN" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?a=UO0TN"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?i=UO0TN" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?a=tt9kn"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?i=tt9kn" border="0"></img></a> </div>http://www.pharmaweblog.com/2008/10/28/off-base-on-off-label-promotion/You might have caught the editorial published today on PLoS Medicine by Fugh-Berman and Melnick, which decries rampant, greed-driven off-label promotion by pharmaceutical marketers.  They suggest that the US government step in with tighter reigns and resist "gutting" current restrictions against off-label promotion. The authors make their argument without providing evidence ...<div class="feedflare"> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?a=h3MHM"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?i=h3MHM" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?a=LUN4M"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?i=LUN4M" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?a=KJN5M"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?i=KJN5M" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?a=GejCm"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?i=GejCm" border="0"></img></a> </div>http://www.pharmaweblog.com/2008/10/23/acomplia-to-be-pulled-in-eu/I haven't written much lately, I know. And now I'm just giving you a news story and some links to previous blog pieces.  Too bad you're not able to cancel your subscription in anger.  It won't be terribly surprising to those of you who've kept an ear to the ground in the ...<div class="feedflare"> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?a=ystzM"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?i=ystzM" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?a=O0M4M"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?i=O0M4M" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?a=0b2wM"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?i=0b2wM" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?a=uXNIm"><img src="http://feeds.feedburner.com/~f/PharmasCuttingEdgePosts?i=uXNIm" border="0"></img></a> </div>